TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
Brief Summary: The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.


Options:
A: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
B: Arm Label: measles-rubella and rotavirus vaccines; Type: EXPERIMENTAL; Interventions: Biological: Rotarix vaccine, Biological: measles-rubella vaccine | Arm Label: measles-rubella vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: measles-rubella vaccine | Intervention Type: BIOLOGICAL; Name: Rotarix vaccine; Assigned to Arm(s): measles-rubella and rotavirus vaccines | Intervention Type: BIOLOGICAL; Name: measles-rubella vaccine; Assigned to Arm(s): measles-rubella and rotavirus vaccines, measles-rubella vaccine
C: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
D: Arm Label: Bivalent OPV 2 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 2 week interval | Arm Label: Bivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 4 week interval | Arm Label: Monovalent OPV 2week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 2 week interval | Arm Label: Monovalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 4 week interval | Arm Label: Trivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 2 week interval; Assigned to Arm(s): Bivalent OPV 2 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 4 week interval; Assigned to Arm(s): Bivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 2 week interval; Assigned to Arm(s): Monovalent OPV 2week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 4 week interval; Assigned to Arm(s): Monovalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Trivalent OPV 4 week interval; Assigned to Arm(s): Trivalent OPV 4 week interval

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Osteoporosis Prevention and Treatment Program: A Disease Management Demonstration Project
Brief Summary: The purpose of this study is to assess the impact of disease management interventions on bone mineral density (BMD) screening rates and osteoporosis treatment rates in women age 65 years or older.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Reminders and opinion leader generated guidelines +/- leaflets and counselling | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Reminders and opinion leader generated guidelines +/- leaflets and counselling; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
C: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
D: Arm Label: CARE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter Reminder and Evaluation Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Catheter Reminder and Evaluation Program; Assigned to Arm(s): CARE

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Osteoporosis Prevention and Treatment Program: A Disease Management Demonstration Project
Brief Summary: The purpose of this study is to assess the impact of disease management interventions on bone mineral density (BMD) screening rates and osteoporosis treatment rates in women age 65 years or older.


Options:
A: Arm Label: Prevention Care Management; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention Care Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention Care Management; Assigned to Arm(s): Prevention Care Management
B: Arm Label: Non-tailored CRC screening brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-tailored CRC screening brochure | Arm Label: Interactive computer intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive computer intervention | Intervention Type: BEHAVIORAL; Name: Non-tailored CRC screening brochure; Assigned to Arm(s): Non-tailored CRC screening brochure | Intervention Type: BEHAVIORAL; Name: Interactive computer intervention; Assigned to Arm(s): Interactive computer intervention
C: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
D: Arm Label: Safety Training; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Safety Training | Arm Label: Personal Health Partner and Counseling (PHP+C); Type: EXPERIMENTAL; Interventions: Behavioral: Personal Health Partner and Counseling (PHP+C) | Intervention Type: BEHAVIORAL; Name: Safety Training; Assigned to Arm(s): Safety Training | Intervention Type: BEHAVIORAL; Name: Personal Health Partner and Counseling (PHP+C); Assigned to Arm(s): Personal Health Partner and Counseling (PHP+C)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Osteoporosis Prevention and Treatment Program: A Disease Management Demonstration Project
Brief Summary: The purpose of this study is to assess the impact of disease management interventions on bone mineral density (BMD) screening rates and osteoporosis treatment rates in women age 65 years or older.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
B: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Allied health professional-run osteoporosis service ("case-management"); Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Osteoporosis Prevention and Treatment Program: A Disease Management Demonstration Project
Brief Summary: The purpose of this study is to assess the impact of disease management interventions on bone mineral density (BMD) screening rates and osteoporosis treatment rates in women age 65 years or older.


Options:
A: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Patients (education, counseling) and Physicians (reminders,1-page guidelines)., Behavioral: Multifaceted intervention | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patients (education, counseling) and Physicians (reminders,1-page guidelines).; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Multifaceted intervention; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): B
C: Intervention Type: BEHAVIORAL; Name: Multifaceted intervention (patient education, physician guidelines, reminders); Assigned to Arm(s): N/A
D: Arm Label: 1 (physician-only); Type: EXPERIMENTAL; Interventions: Other: Information letters | Arm Label: 2 (physician/patient); Type: EXPERIMENTAL; Interventions: Other: Information letters | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Information letters; Assigned to Arm(s): 1 (physician-only), 2 (physician/patient)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Electronic cigarettes; Type: EXPERIMENTAL; Interventions: Other: disposable electronic cigarettes | Intervention Type: OTHER; Name: disposable electronic cigarettes; Assigned to Arm(s): Electronic cigarettes
D: Arm Label: 0.8 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.26 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.12 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.07 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.03 mg nicotine with 9 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: 0.04 mg nicotine with 13 mg tar; Type: EXPERIMENTAL; Interventions: Other: very low nicotine content cigarettes | Arm Label: Usual brand; Type: OTHER; Interventions: Other: very low nicotine content cigarettes | Intervention Type: OTHER; Name: very low nicotine content cigarettes; Assigned to Arm(s): 0.03 mg nicotine with 9 mg tar, 0.04 mg nicotine with 13 mg tar, 0.07 mg nicotine with 9 mg tar, 0.12 mg nicotine with 9 mg tar, 0.26 mg nicotine with 9 mg tar, 0.8 mg nicotine with 9 mg tar, Usual brand

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: Electronic cigarette with or without nicotine; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic cigarette | Arm Label: Smoker control; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional cigarette | Intervention Type: OTHER; Name: Electronic cigarette; Assigned to Arm(s): Electronic cigarette with or without nicotine | Intervention Type: OTHER; Name: Conventional cigarette; Assigned to Arm(s): Smoker control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose
B: Arm Label: Placeo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: St. John's Wort-900 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-900 mg/day | Arm Label: St. John's Wort-1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: St. John's Wort-1800mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placeo | Intervention Type: DRUG; Name: St. John's Wort-900 mg/day; Assigned to Arm(s): St. John's Wort-900 mg/day | Intervention Type: DRUG; Name: St. John's Wort-1800mg/day; Assigned to Arm(s): St. John's Wort-1800 mg/day
C: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Nicotine gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Bupropion+Nicotine Gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion | Arm Label: Double placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion, Bupropion+Nicotine Gum, Double placebo, Nicotine gum
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking
Brief Summary: The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Varenicline pre-treatmemt; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Placebo, Varenicline pre-treatmemt | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A